Nymox Pharm Financials

No, Nymox Pharm (NYMXF) reported a net income of -$4.5M in fiscal year 2024.

Nymox Pharm (NYMXF) generated -$2.6M in free cash flow during fiscal year 2024. This represents a 35.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Nymox Pharm (NYMXF) generated -$2.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Nymox Pharm (NYMXF) had $654K in total assets as of fiscal year 2024, including both current and long-term assets.

Nymox Pharm (NYMXF) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Nymox Pharm (NYMXF) had 95M shares outstanding as of fiscal year 2024.

Nymox Pharm (NYMXF) had a current ratio of 0.09 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

Nymox Pharm (NYMXF) had a debt-to-equity ratio of -1.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Nymox Pharm (NYMXF) had a return on assets of -686.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Nymox Pharm (NYMXF) had $74K in cash against an annual operating cash burn of $2.6M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Nymox Pharm (NYMXF) has negative shareholder equity of -$6.8M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Nymox Pharm (NYMXF) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Nymox Pharm (NYMXF) has an earnings quality ratio of 0.58x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.